Amid global market volatility, TipRanks offers valuable tools to guide investors. One of the most powerful is the Smart Score, which assigns a ranking of one to ten to stocks and highlights their potential to outperform the broader market. Using this tool, we have identified three standout stocks: Protagonist Therapeutics (PTGX), Praxis Precision Medicines (PRAX), and Disc Medicine (IRON). Each of these has earned a top Smart Score and a Strong Buy rating from Wall Street analysts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The TipRanks’ Smart Score rates the stocks on a scale from 1 to 10, with 10 being the highest. The score is based on eight key market factors, including Wall Street analyst ratings, insider transactions, financial blogger opinions, and more. Additionally, the Top Smart Score Stocks list offers a comprehensive selection of stocks rated a perfect 10, along with advanced filtering options.
Let’s dive into the details.
Is Protagonist a Good Investment?
Protagonist Therapeutics is a biopharmaceutical company developing peptide-based medicines to treat serious diseases. Year-to-date, PTGX stock has gained almost 90%.
Looking ahead, Wall Street analysts remain bullish, with all 11 covering analysts giving it a Buy rating. Meanwhile, the Protagonist’s average stock price target of $78.89 suggests a potential upside of 8% from current levels.
What Is the Price Target for Praxis Stock?
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system (CNS) disorders.
Year-to-date, PRAX stock has gained 140%. Nonetheless, Wall Street analysts remain bullish on its upside potential, with 13 out of 14 analysts covering PRAX stock, rating it as a Buy. According to TipRanks, the stock has a price target of $285.36, implying 54.5% upside from current levels.
What Is the Stock Price Prediction for Disc Medicine?
Disc Medicine develops innovative treatments for hematologic diseases. So far in 2025, IRON stock has gained 35%.
IRON stock carries a Strong Buy rating, with 11 Buys assigned in the past three months. The average stock price target of Disc Medicine is $111.11, which implies a potential upside of 30.09%.
